National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Ibrutinib (Imbruvica®) in combination with venetoclax. HTA ID: 22054

Ibrutinib in combination with venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia.

 

NCPE Assessment Process Complete
Rapid review commissioned 27/07/2022
Rapid review completed 02/09/2022
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of ibrutinib in combination with venetoclax compared with the current standard of care.